GSK (GSK) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the approval of Nucala, a monoclonal antibody targeting interleukin-5, in adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease, COPD, characterised by raised blood eosinophils on a combination of an inhaled corticosteroid, ICS, a long-acting beta2-agonist, LABA, and a long-acting muscarinic antagonist, LAMA.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA CHMP recommended expanding indication of its RSV vaccine
- Blujepa approved by FDA as oral option for treatment of urogenital gonorrhea
- GSK price target raised to 1,500 GBp from 1,200 GBp at HSBC
- GSK announces GSK’277 received ODD from FDA to treat SCLC
- Ideaya disclosed termination of GSK license agreement